| Prev Close | 49.89 |
| Open | 49.58 |
| Day Low/High | 49.37 / 49.93 |
| 52 Wk Low/High | 37.62 / 51.84 |
| Volume | 1.61M |
| Avg Volume | 2.61M |
Sanofi (SNY)
49.53
0.36
0.72
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 2.51B |
| Market Cap | 124.08B |
| EPS | 1.30 |
| P/E Ratio | 26.61 |
| Div & Yield | 1.17 (2.39%) |
Mylan Still Isn't Cheap
The EpiPen controversy makes this stock a shot in the dark.
Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin
Clinton goes after the drug companies again -- for starters.
Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Biotechs Rally on Pfizer/Medivation Deal
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Pfizer Is Buying Medivation for $14 Billion
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Bret Jensen Reporting for Duty
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
It's 'All Systems Go' for Biotech
The sector seems to be rebounding after tumbling by more than 40%.
Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg
The mobile-gaming market is expected to surpass console games this year, according to Deloitte.
Sanofi's Chart Shows Promise
Our first upside target is the $50 to $52 area and a close below $40 would extend the base.
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Morning Movers: BCS, LYG, RBS, GOLD, AU, SNY
U.K. banks continue to get crushed in the wake of last week's Brexit vote as gold, a typical safe-haven investment, surged ahead.
BioMarin Pharmaceuticals Jumps on Takeover Talk
Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.
Biotech M&A Waking Up After Long Nap
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
Biotech Is Showing Some Bargains
It is hard to see much growth in the market overall, until earnings growth returns.
Cramer: Worst May Be Over for Embattled Pharma
The M&A activity is an incredible and a welcome sign.
M&A Could Ignite Next Leg Up for Biotech
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
A Good Morning So Far
The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...
Novice Trade: GlaxoSmithKline
Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
MannKind Investors Should Have Seen the Writing on the Wall
Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.
2016 Could Be the Year of the Eurozone Stock Markets
The ECB's monetary stimulus is working, and more may be on the way.
2 Speculative Biotech Stocks for 2016
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
U.S. Carmakers Benefit the Most From Jump in European Car Sales
And four other things you need to know now.
Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
Closing Bell: Sanofi Falls on Weak Diabetes Sales; Crude Tops $46
Stocks ended the day lower in a quieter session of trading compared to Wednesday's blowout rally.
Building a Sweet 16 Portfolio, Part 1
Selection of stocks is tailor made for investor, given market parameters.
Sanofi, Marks & Spencer Offer European Value Says S&P Capital IQ
The European economy is growing and the volatility from the Greek exit drama is keeping a lid on stock valuations.
Here Are 3 Charts Showing You Why Illumina Is a Marvel
It's almost impossible to get too excited about its success.
Obamacare Ruling Means the Debate Is Over
As health-care stocks rally, it's time for politicians to move on.
What's So Great About an Up Opening?
Don't rely on Europe; it's too out of sync with U.S.
